Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention-Reference-Cited by-同舟云学术

Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention

Published:2022-11 Issue:22 Volume:15 Page:2270-2280
ISSN:1936-8798
Container-title:JACC: Cardiovascular Interventions
language:en
Short-container-title:JACC: Cardiovascular Interventions

Author:

Koshy Anoop N.,Giustino Gennaro,Sartori Samantha,Kyaw Htoo,Yadav Mayank,Zhang Zhongjie,Hooda Amit,Farooq Ali,Krishnamoorthy Parasuram,Sweeny Joseph M.,Khera Sahil,Serrao Gregory W.,Sharma Raman,Suleman Javed,Dangas George,Kini Annapoorna S.,Mehran Roxana,Sharma Samin K.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

2. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Levine;J Am Coll Cardiol,2016

3. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Lawton;J Am Coll Cardiol,2022

4. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Collet;Eur Heart J,2021

5. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial;James;Eur Heart J,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. It Is Time to Overcome the “One-Size-Fits-All” Approach in Chronic Coronary Syndrome?;The American Journal of Cardiology;2024-05

2. Reply;Journal of the American College of Cardiology;2024-05

3. Antithrombotic Treatment in Coronary Artery Disease;Current Pharmaceutical Design;2023-10

4. Rosuvastatin plus ticagrelor decreases the risk of major adverse cardiovascular events and elevates cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention: A meta‑analysis;Experimental and Therapeutic Medicine;2023-09-25

5. Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute Coronary Syndrome;The American Journal of Cardiology;2023-07